• SENSEX 78,009.25
    -70.71 (--0.09%)
  • BANKNIFTY 57,491.10
    -144.15 (--0.25%)
  • ICICI Pru Life
    511.95 706.50(%)
  • HDFC Bank
    729.65 1,020.35(%)
  • Apollo Hospitals
    8,925.00 9,326.80(%)
  • Wework India
    700.00 419.60(%)
  • LG Electronics
    1,736.35 1,736.40(%)
  • Gland Pharma
    3,039.00 3,039.00(%)
  • Bharti Airtel
    2,005.65 2,174.70(%)
  • Leap India
    143.10 143.10(%)
  • Blue Star
    1,497.00 1,450.00(%)
  • Cupid
    288.00 32.76(%)
  • Netweb Technol.
    4,995.00 2,037.65(%)
  • Honasa Consumer
    509.90 509.90(%)
  • Manorama Indust.
    1,867.00 1,867.00(%)
  • Vodafone Idea
    14.17 15.35(%)
  • Technocraft Ven.
    334.60 334.60(%)
  • Bharat Dynamics
    1,420.00 1,655.25(%)
  • Dixon Technolog.
    14,210.00 18,471.50(%)
  • Billionbrains
    194.60 112.02(%)
  • Infosys
    1,159.00 984.00(%)
  • Gujarat Fluoroch
    4,897.00 4,959.45(%)
  • Overview
  • Key Ratios
  • Financials
  • Shareholding
  • Company Info
  • Peer Comparison
Overview
  • Overview
  • Key Ratios
  • Financials
  • Shareholding
  • Company Info
  • Peer Comparison

Samrat Pharmachem Ltd Pharmaceuticals - Indian - Bulk Drugs

  • Indian Private
  • BSE Code : 4878.0
  • ISIN : INE103E01016
231.20 -9 (-3.81%)
  • As on 15 Aug 2026 (EOD)

  • Today’s Low

    228.35

  • Today’s High

    249.90

  • Open

    248.50

  • Perv Close

    240.35

  • 52W Low

    190.00

  • 52W High

    339.90

Key Indicators

  • P/E(TTM)

    0.00

  • Mar.Cap (₹Cr.)

    71.43

  • Div & Yield %

    0.00

  • Book Value(₹)

    220.67

  • Debt-Equity Ratio

    -3.81

  • AGM Date

    14-Aug-2026

  • EPS

    0.00

  • P/E Ratio

    0.00

Financials Ratios

  • Debt-Equity Ratio

    -

  • Mar.Cap (₹Cr.)

    71.43

  • RONW (%)

    -

  • ROCE (%)

    -

Score Board

  • Equity (₹ in Cr.)

    3.09

  • BV (₹)

    220.70

  • Sales( ₹ in Cr.)

    289.72

  • NP (in Cr.)

    -3.31

  • NP Var(%)

    -148.0

  • Div%

    0.0

  • CPS (₹)

    -8.40

  • EPS (₹)

    -10.70

  • Traded Value (₹ in Lakhs)

    71.43

  • 52 Week High

    339.90

  • 52 Week Low

    190.00

  • Price BSE

    231.0

  • Price NSE

    0.00

  • Market Capital( in Cr.)

    71.43

  • P/C Ratio

    -27.50

  • P/E Ratio

    -21.50

  • Price Vs.BV

    -10.70

View More
Invest Now!

Navigate The Market With Confidence

Your all-in-one destination for expert investment guidance and streamlined portfolio management solutions

Financials

All Values are in (₹Cr)
Particulars(INCOME) 2025 Mar 2024 Mar 2023 Mar 2022 Mar 2021 Mar 2020 Mar
INCOME :            
Sales Turnover 285.86 281.58 310.65 221.75 204.37 157.12
Excise Duty 0.00 0.00 0.00 0.00 25.35 19.66
Net Sales 285.86 281.58 310.65 221.75 179.02 137.46
Other Income 0.97 1.38 0.48 0.63 0.46 0.57
Stock Adjustments 2.52 -4.84 10.14 0.33 -2.23 6.18
Total Income 289.35 278.12 321.27 222.71 177.25 144.21
EXPENDITURE :            
Raw Materials 269.27 265.48 288.00 190.23 162.02 131.80
Power and Fuel Cost 1.39 1.37 1.46 1.34 1.12 0.91
Employee Cost 1.11 1.11 1.07 0.96 1.05 1.00
Other Manufacturing Expenses 2.28 2.04 2.47 2.29 1.65 1.34
Selling and Administration Expenses 3.38 3.62 3.10 2.46 1.83 1.83
Miscellaneous Expenses 0.70 0.66 0.76 0.55 0.47 0.13
Employee Benefit Expenses 1.11 1.11 1.07 0.96 1.05 1.00
Less: Preoperative Expenditure 0.00 0.00 0.00 0.00 0.00 0.00
Total Expenses 278.14 274.27 296.85 197.84 168.14 137.02
Operating Profit 11.21 3.86 24.40 24.87 9.12 7.19
Interest 0.67 0.69 1.23 0.67 1.28 0.98
Gross Profit 10.54 3.17 23.17 24.20 7.84 6.21
Depreciation 0.65 0.65 0.64 0.59 0.49 0.43
Profit Before Tax 9.89 2.52 22.53 23.61 7.35 5.78
Current Tax 3.00 0.28 6.11 6.39 1.72 1.73
Fringe Benefit tax 0.00 0.00 0.00 0.00 0.00 0.00
Deferred Tax -0.23 0.08 -0.21 0.03 0.29 -0.18
Reported Net Profit 7.11 2.16 16.63 17.18 5.33 4.24
Extraordinary Items 0.22 0.89 0.00 -0.02 -0.01 -0.01
Adjusted Net Profit 6.89 1.27 16.63 17.20 5.34 4.25
Adjustment below Net Profit 0.00 0.00 0.00 0.00 0.00 0.00
P & L Balance brought forward 61.91 60.05 43.73 26.55 21.21 16.98
Statutory Appropriations 0.00 0.00 0.00 0.00 0.00 0.00
Appropriations 0.31 0.31 0.31 0.00 0.00 0.00
P & L Balance carried down 68.71 61.91 60.05 43.73 26.55 21.21
Dividend 0.00 0.00 0.00 0.00 0.00 0.00
Preference Dividend 0.00 0.00 0.00 0.00 0.00 0.00
Equity Dividend (%) 10.00 10.00 10.00 10.00 0.00 0.00
Dividend Per Share(Rs) 1.00 1.00 1.00 1.00 0.00 0.00
Earnings Per Share-Unit Curr 23.02 7.00 53.83 55.62 17.26 13.71
Earnings Per Share(Adj)-Unit Curr 23.02 7.00 53.83 55.62 17.26 13.71
Book Value 232.39 210.37 204.37 151.54 95.92 78.66
Book Value(Adj)-Unit Curr 232.39 210.37 204.37 151.54 95.92 78.66

Shareholding Pattern

  • Promoter Group

    49.09%

  • Public Share Holding

    50.91%

Category of Shareholder No of Shares % Holdings Demat Shares Shareholders
A]. Promoter & Group
Foreign (Promoter & Group) - Bodies Corporate 0 0.00 0 0
Foreign (Promoter & Group)-Individuals (Non-Resident / Foreign) 0 0.00 0 0
Foreign Promoter(Institutional) 0 0.00 0 0
Promoter Others 0 0.00 0 0
Sub Total 0 0.00 0 0
[2] INDIAN
Bodies Corporate-Indian (Promoter & Group) 0 0.00 0 0
Government(Central / State)-Indian (Promoter & Group) 0 0.00 0 0
Directors & their Relatives-Indian (Promoter & Group) 0 0.00 0 0
Financial Institutions / Banks-Indian (Promoter & Group) 0 0.00 0 0
Individuals / Hindu Undivided Family-Indian (Promoter & Group) 1,516,767 49.09 1,516,767 10
Partnership Firms-Indian (Promoter & Group) 0 0.00 0 0
Persons Acting in Concert 0 0.00 0 0
Trusts 0 0.00 0 0
Others 0 0.00 0 0
Sub Total 1,516,767 49.09 1,516,767 10
Total ShareHolding for Promoter & Group
B]. Publice Share Holding
1] Institution
Government(Central / State) 0 0.00 0 0
Clearing Members 0 0.00 0 0
Corporate Bodies 0 0.00 0 0
Foreign Direct Investments 0 0.00 0 0
Financial Institutions / Banks 0 0.00 0 0
Foreign Bank 0 0.00 0 0
Foreign Bodies Corporate/OCBs/FBC 100,000 3.24 0 1
Foreign Collaborators 0 0.00 0 0
Foreign Institutional Investors 0 0.00 0 0
Foreign Venture Capital Investors 0 0.00 0 0
Foreign Institution Other 0 0.00 0 0
Insurance Companies 0 0.00 0 0
Mutual Funds / UTI 0 0.00 0 0
Individuals (Non-Resident / Foreign) 0 0.00 0 0
NSDL Intransit 0 0.00 0 0
Others 0 0.00 0 0
Trusts 0 0.00 0 0
Venture Capital Funds 0 0.00 0 0
Sub total 100,000 3.24 0 1
2] Non Institution
Bodies Corporate 85,425 2.76 38 40
Clearing Members 96 0.00 96 1
Directors of their Relatives 0 0.00 0 0
Employees 0 0.00 0 0
Escrow Account 0 0.00 0 0
Foreign Corporate Bodies 0 0.00 0 0
Foreign Direct Investments 0 0.00 0 0
NRIs/Foreign Individuals/Foreign Nationals 60,380 1.95 119 119
Foreign Non Institution Other 0 0.00 0 0
Hindu Undivided Families 42,996 1.39 42,996 111
Indian Public 0 0.00 0 0
Individuals holding nominal share capital in excess of Rs. 1 lakh 173,757 5.62 173,757 3
Individuals holding nominal share capital up to Rs. 1 lakh 1,108,836 35.89 5,447 6,041
Market Maker 0 0.00 0 0
NSDL Transit 0 0.00 0 0
Shares in transit 0 0.00 0 0
Societies 0 0.00 0 0
Trust & Foundation 0 0.00 0 0
Others 543 0.02 543 2
Sub Total 1,472,933 47.67 223,396 6,319
Total Public Shareholding
C]. Shares held by Custodians and against which Depository Receipts have been issued
ADR 0 0.00 0 0
GDR 0 0.00 0 0
Other Custodians 0 0.00 0 0
Total Shares held by Custodians and against which Depository Receipts have been issued 0 0.00 0 0
Grand Total ( A + B + C ) 3,089,700 100.00 1,740,163 6,330

Company Background

Samrat Pharmachem LtdPharmaceuticals - Indian - Bulk Drugs

  • Samrat Pharmachem Ltd
  • BSE Code : 4878.0
  • ISIN : INE103E01016

  • Incorporation Year

    1992

  • Registered Office

    Plot No A2/3445
    GIDC Phase IV, Ankleshwar,
    Gujarat-393002

  • Telephone

    91-2646-220774

  • FAX

    91-2646-251291

  • Chairman

    Lalit Mehta

  • Managing Director

    Lalit Mehta

  • Company Secretary

    Nishant Kankaria

  • Auditor

    Shah & Savla LLP

  • Face Value

    10

  • Listing

    BSE

  • Registrar

    Link Intime India Pvt Ltd
    C-13 Pannalal Silk,
    Mills Cmpd LBS Marg,Bhandup West
    Mumbai - Mumbai - 400 078

Samrat Pharmachem Ltd Peer Comparison

Profit & Loss
Financial Ratios
Balance Sheet
Select Company Name LTP (₹) Revenue Sales P/E Ratio ROCE %
Samrat Pharma 231.20 286.83 285.86 -21.57 13.60
Abbott India 27,076.90 7,217.19 6,929.05 35.63 43.78
Astrazeneca Phar 7,753.70 2,304.07 2,275.58 114.28 27.86
Glaxosmi. Pharma 2,689.10 3,932.76 3,790.20 42.96 58.17
Novartis India 1,586.70 398.23 356.27 40.07 16.64
Cipla 1,450.00 20,102.60 18,979.95 38.11 13.88
Bliss GVS Pharma 524.05 773.53 729.81 48.66 12.51
Amrutanjan Healt 494.75 469.50 451.82 26.50 21.89
Fermenta Biotec. 449.40 474.15 450.25 20.98 18.77
Guj. Themis Bio. 349.05 152.47 150.80 78.09 27.21
Ambalal Sarabhai 42.47 19.52 3.94 78.65 6.77